Sheng X*, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C, Liu Z, Guo H, Yu G, Ji Z, Ying J, Ling Y, Yu S, Hu Y, Guo J, Fang J, Zhou A*, Guo J*. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.,J Clin Oncol,2024 Apr 20;42(12):1391-1402.

Tang B#, Duan R#, Fan Z, Yan X, Li S, Zhou L, Li J, Xu H, Mao L, Lian B, Wang X, Bai X, Wei X, Li C, Cui C, Si L, Chi Z, Guo J, Sheng X*. Natural history of bone-only metastasis in renal cell carcinoma.,Urol Oncol,2024 Apr;42(4):119.e17-119.e22.

Ya'nan Ren#, Teli Liu#, Siming Li#, Xiaokun Ma, Lei Xia, Pei Wang, Qian Guo, Yuan Yao, Xingguo Hou, Xi'nan Sheng*, Hua Zhu*, Zhi Yang*. An iodine?labelled Antibody–drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.,International Journal of Pharmaceutics,,651, 123756.

Yan XQ#, Ye MJ#, Zou Q#, Chen P, He ZS, Wu B, He DL, He CH, Xue XY, Ji ZG, Chen H, Zhang S, Liu YP, Zhang XD, Fu C, Xu DF, Qiu MX, Lv JJ, Huang J, Ren XB, Cheng Y, Qin WJ, Zhang X, Zhou FJ, Ma LL, Guo JM, Ding DG, Wei SZ, He Y, Guo HQ, Shi BK, Liu L, Liu F, Hu ZQ, Jin XM, Yang L, Zhu SX, Liu JH, Huang YH, Xu T, Liu B, Sun T, Wang ZJ, Jiang HW, Yu DX, Zhou AP, Jiang J, Luan GD, Jin CL, Xu J, Hu JX, Huang YR, Guo J, Zhai W*, Sheng XN*. Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study.,Ann Oncol,2024 Feb;35(2):190-199

Qu M, Zhou L, Yan X, Li S, Wu X, Xu H, Li J, Guo J, Zhang X, Li H*, Sheng X*. Advances in HER2-Targeted Treatment for Advanced/Metastatic Urothelial Carcinoma.,Bladder (San Franc).,2023 Dec 11:10:e21200012

Duan X, Xia L, Zhang Z, Ren Y, Pomper MG, Rowe SP, Li X, Li N, Zhang N, Zhu H, Yang Z*, Sheng X*, Yang X*. First-in-human study of the radioligand 68Ga-N188 targeting nectin-4 for PET/CT imaging of advanced urothelial carcinoma.,Clin Cancer Res,2023 Apr 24;CCR-23-0609.

Zhou L#, Shao Z#, Liu Y, Yan X, Li J, Wu X, Tang B, Li S, Cui C, Chi Z, Si L, Kong Y, Mao L, Lian B, Wang X, Bai X, Dai J, Guo J, Sheng X*. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.,Oncologist,2023 Mar 27:oyad070.

Huizi Lei, Yun Ling, Pei Yuan, Xieqiao Yan, Lin Wang, Yanxia Shi, Xin Yao, Hong Luo, Benkang Shi, Jiyan Liu, Zhisong He, Guohua Yu, Weiqing Han, Changlu Hu, Zhihong Chi, Chuanliang Cui, Lu Si, Jianmin Fang, Jun Guo, Xinan Sheng*, Aiping Zhou*, Jianming Ying*.Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.,Journal of the National Cancer Center,2023;3(2), 121-128

Sheng X*, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Yuan X, Guo J*. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT),Eur J Cancer,2023 Jan;178:205-215.

Zhou L#, Liu Y#, Mo J, Cui C, Chi Z, Si L, Kong Y, Yan X, Li S, Wu X, Li J, Xu H, Cao D, Guo J, Sheng X*. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma.,Urol Oncol,2022 Aug;40(8):385.e1-385.e8.

Yan X, Zhou L, Li S, Wu X, Cui C, Chi Z, Si L, Kong Y, Tang B, Li C, Mao L, Wang X, Lian B, Bai X, Dai J, Guo J, Sheng X*. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.,Clin Genitourin Cancer,2022 Aug;20(4):354-362

Li S, Wu X, Yan X, Zhou L, Chi Z, Si L, Cui C, Tang B, Mao L, Lian B, Wang X, Bai X, Dai J, Kong Y, Tang X, Feng H, Yao S, Flaherty KT, Guo J*, Sheng X*. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.,J Immunother Cancer,10(2):e004036

Sheng X#, Chen H#, Hu B, Yao X, Liu Z, Yao X, Guo H, Hu Y, Ji Z, Luo H, Shi B, Liu J, Wu J, Zhou F, He Z, Fan J, Wang W, Feng H, Yao S, Keegan P, Huang Y, Guo J*. Safety, Efficacy and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03,Clin Cancer Res,28(3):489-497

Tang B#, Mo J#, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J*, Sheng X*. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.,Eur J Cancer,156:83-92.

Tang B, Mo J, Yan X, Duan R, Chi Z, Cui C, Si L, Kong Y, Mao L, Li S, Zhou L, Lian B, Wang X, Bai X, Xu H, Li C, Dai J, Guo J*, Sheng X*. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.,Eur J Cancer.,2021 Aug 20; 156:83-92.

Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Ying J, Han W, Hu C, Ling Y, Chi Z, Cui C, Si L, Fang J, Zhou A*, Guo J*. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma.,Clin Cancer Res,2021 Jan 1;27(1):43-51.

Wang S, Zhu H, Ding J, Wang F, Meng X, Ding L, Zhang Y, Li N, Yao S, Sheng X*, Yang Z*. Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. Clin Nucl Med.,Clin Nucl Med,2021 May 1;46(5):382-388.

Yan X#, Sheng X#, Chi Z, Si L, Cui C, Kong Y, Tang B, Mao L, Wang X, Lian B, Li S, Bai X, Zhou L, Dai J, Yao H, Guo J*. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma.,J Clin Oncol,2021,39(8):881-889

Li X#, Li S#, Chi Z, Cui C, Si L, Yan X, Mao L, Lian B, Tang B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Guo J, Sheng X*. Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma.,Urol Oncol,2020 Jul 9:S1078-1439(20)30277-5.

Huang H, Zhu H, Xie Q, Tian X, Yang X, Feng F, Jiang Q, Sheng X*, Yang Z*. Evaluation of 124I-JS001 for hPD1 immuno-PET imaging using sarcoma cell homografts in humanized mice.,Acta Pharm Sin B,2020;10(7):1321-1330

Sheng X, Jin J, He Z, Huang Y, Zhou A, Wang J, Ren X, Ye D, Zhang X, Qin S, Zhou F, Wang B, Guo J. Pazopanib Versus Sunitinib in Chinese Patients With Locally Advanced or Metastatic Renal Cell Carcinoma: Pooled Subgroup Analysis From the Randomized, COMPARZ Studies,BMC Cancer,2020 Mar 14;20(1):219

Sheng X#, Yan X#, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J*. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.,EBioMedicine,2020 May;55:102755

肿瘤生物治疗学, 参编, 人民卫生出版社, 2021.5

晚期泌尿肿瘤的临床与转化医学研究

粘膜黑色素瘤综合治疗

CXCL17调控巨噬细胞重编程介导HER2阳性尿路上皮癌免疫治疗耐受的机制研究, 课题负责人, 2025.1.1～2028.12.31, 国 家自然科学基金委员会

抗体偶联药物联合免疫治疗肌层浸润性膀胱癌的机制及潜在标志物研究, 课题负责人, 2024.10.1～2027.9.30, 北京市自然科学基金-昌平创新联合基金 重点研究专题项目

HER2阳性尿路上皮癌抗体偶联药物继发性耐药的机制及逆转耐药的干预研究, 课题负责人, 2022.1.1～2025.12.31, 国 家自然科学基金委员会

基于基因表达谱分析的阿昔替尼联合PD-1 单抗治疗转移性肾癌疗效预测模型的构建, 课题负责人, 2023.1.1～2025.12.1, 北京市希思科临床肿瘤学研究基金会

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2025	肿瘤内科学	长学制	专业学位	临床技能训练与研究	长学制二级学科培养
2025	肿瘤内科学	博士	专业学位	临床技能训练与研究	申请考核制
2025	肿瘤学	博士	科学学位	泌尿肿瘤的临床与转化医学研究	申请考核制
2025	肿瘤内科学	硕士	专业学位	临床技能训练与研究	全国统考